Drug intelligence / Profile preview

CL-AT-513

Development stage: Preclinical
Lead developer: Charleston Laboratories
Modality: Small Molecules

Overview

**CL-AT-513** is a confidential preclinical respiratory drug candidate developed by Charleston Laboratories. The sponsor's public pipeline identifies it only as a confidential molecule in its respiratory portfolio; the active ingredients, molecular targets, mechanism of action, specific respiratory indication, formulation, and route of administration have not been publicly disclosed. Publicly available pipeline metadata categorizes the program as a small-molecule combination. ([charlestonlabs.com](https://charlestonlabs.com/pipeline/respiratory/))

Beyond the preview

Go deeper on CL-AT-513.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CL-AT-513.

Explore the full profile